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Graft-versus-host disease, iron overload, and infections are the major causes of liver dysfunction in allogeneic
hematopoietic stem cell transplantation (AHSCT) recipients. We investigated the relationship between serum
iron parameters and the levels of transforming growth factor-b (TGF-b), ﬁbroblast growth factor (FGF),
endothelin-1 (ET-1), and nitric oxide (NO) as predictors of chronic liver injury in 54 AHSCT recipients who
survived at least a year after transplantation. Serum samples from patients were obtained for the evaluation
of ET-1, TGF-b, FGF, NO, and nontransferrin bound iron at the ﬁrst year follow-up visit using commercially
available ELISA kits. Patients were categorized depending on serum ferritin and transferrin saturation levels.
The parameters were compared between the groups, and survival analysis was also performed. Most of the
AHSCT recipients (81.5%) were in complete remission during the study. After a median follow-up time of 73
months (range, 13 to 109 months), 72.2% of the patients were alive. Mean serum levels of ET-1, NO, TGF-b, and
FGF were 81.54  21.62 mmol/mL, 31.82  26.42 mmol/mL, 2.56  0.77 ng/mL, and 50.31  32.69 pg/mL,
respectively. Nineteen patients (35.2% of the cohort) had serum ferritin levels higher than 1000 ng/mL. Mean
S¸.Z. Akı et al. / Biol Blood Marrow Transplant 21 (2015) 934e953 949serum levels of ET-1, NO, TGF-b, and FGF were similar in patients with serum ferritin levels below or above
1000 ng/mL (P > .05). Serum ferritin levels were positively correlated with serum alanine aminotransferase
(r ¼ .284, P ¼ .042) and g-glutamyl transferase (r ¼ .271, P ¼ .05) levels and were negatively correlated with
serum albumin levels (r ¼ .295, P ¼ .034). There was a signiﬁcant positive correlation between serum
transferrin saturation and alanine aminotransferase levels (r ¼ .305, P ¼ .03). Serum ET-1 level was positively
correlated with alkaline phosphatase levels (r ¼ .304, P ¼ .026). In univariate Cox regression analysis serum
levels of iron parameters, ET-1, NO, TGF-b, and FGF did not have an impact on overall survival (P > .05). The
probability of progression-free survival was also similar in patients with ferritin levels above or below 1000
ng/mL (P ¼ .275). The probability of survival was similar in patients with transferrin saturation 70% and
<70% (P > .05). Serum iron parameters showed a positive correlation with liver injury. However, there was no
correlation between ﬁbrogenic cytokines and liver transaminases. Our results suggest that iron overload at
least with the current levels of ferritin might have a relatively benign course. Prospective randomized trials
will guide the actual role of iron chelation in the post-transplantation setting.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION patients had their samples already stored at the 1-year follow-up,
Liver dysfunction is frequently seen in allogeneic he-
matopoietic stem cell transplantation (AHSCT), and chronic
graft-versus-host disease (GVHD), iron overload (IO), and in-
fections per se or in combination are responsible for most
cases [1]. These factors, directly or indirectly through the in-
duction of cytokines, might lead to chronic liver injury [2].
Repeated red cell transfusions, increased gastrointestinal iron
absorption due to inﬂammatory peritransplant conditions
caused by chemotherapy and GVHD, and ineffective eryth-
ropoiesis are the major causes of IO in HSCT recipients [3,4].
Excess iron results in the appearance of nontransferrin-
bound iron (NTBI), which mediates direct tissue injury and
organ toxicity. NTBI corresponds to iron unbound to trans-
ferrin, heme, or ferritin iron. The main form of NTBI as iron
(III) citrate is efﬁciently taken up by the liver [4,5]. Excess
iron can damage tissues by catalyzing the conversion of su-
peroxide and hydrogen peroxide to free radical species by
attacking cellular membranes, proteins, and DNA [6].
The impact of pretransplantation IO on survival and
treatment-related complications has been reviewed exten-
sively [4,7-12]. Although a previous report claims that IO is
persistent up to 2 years and preserves its adverse prognostic
signiﬁcance [13], the clinical and prognostic signiﬁcance of
persistent IO post-transplantation has not yet been fully
clariﬁed. Hepatic IO was previously found as a major cause of
hepatic injury post-AHSCT, and serum ferritin was found to
be correlated to the histological grade of iron in the hepa-
tocytes [14]. A similar prospective observational study in-
dicates a strong correlation between liver iron content,
serum ferritin level, and the number of transfusions a year
after transplantation [15].
Despite the increased frequency and the well-established
early effects, the impact of IO on the long-term morbidity
and/or mortality of HSCT has not yet been established. The
aim of our study was to analyze the incidence and extent of
IO after HSCT. We also investigated the interaction between
the serum iron parameters and serum levels of transforming
growth factor-b (TGF-b), ﬁbroblast growth factor (FGF),
endothelin-1 (ET-1), and nitric oxide (NO) as predictors of
liver injury in AHSCT recipients with persistent IO.METHODS
Fifty-four consecutive adult AHSCT recipients who lived at least 1 year
after HSCT were included in this study. Serum samples are routinely stored
at the 1-year follow-up visit per institutional practice. Written informed
consent was obtained from all patients before transplantation for a fraction
of their blood samples obtained for routine tests at follow-up visits to be
stored for any further potential study per institutional practice. Forty-onewhereas 13 patients had their serum samples collected prospectively after
approval of the Institutional Review Board and obtaining informed consents
from the patients. AHSCT recipients who were conditioned with a myeloa-
blative regimen received cyclosporine A from day 1 and methotrexate on
days þ1, þ3, þ6, and þ11 for the prevention of GVHD. Patients conditioned
with a nonmyeloablative regimen received cyclosporine A from day 1 and
mycophenolate mofetil from day þ1 as GVHD prophylaxis.
Serum samples for the analysis of ET-1, TGF-b, FGF, NO, and NTBI were
obtained at the ﬁrst year post-transplant visit and stored at 80C until
analysis. Serum ferritin and transferrin saturation (TS) levels, acute phase
reactant levels, serum albumin, and alanine aminotransferase, aspartate
aminotransferase, g-glutamyl transferase, and alkaline phosphatase were
studied using a modular autoanalyzer (Cobas Integra 800; Roche, Indian-
apolis, IN). Serum NTBI levels were measured using the method described
previously by Gosriwatana et al. [16]. ET-1, NO (Cayman Company, Ann
Arbor, MI), TGF-b, and FGF (Invitrogen, Carlsbad, CA) levels were measured
using commercially available ELISA kits. Patients were grouped according to
the serum ferritin levels as <1000 ng/mL versus 1000 ng/mL and for TS as
<70% versus 70%. National Institutes of Health criteria were used to
categorize acute and chronic GVHD [17]. Disease stage was categorized as
early, intermediate, and late according to the European Group for Blood and
Marrow Transplantation risk score [18].Statistical Analysis
The statistical evaluation of the data was performed using SPSS soft-
ware, version 21 (SPSS Inc, Chicago, IL). Differences between groups were
analyzed by the Mann-Whitney U test. Correlation between variables were
evaluated using Pearson or Spearman’s correlation tests where appropriate.
A value of P < .05 was considered to represent a statistically signiﬁcant
difference. Survival analysis was carried out by using Kaplan-Meier and log-
rank tests.RESULTS
Fifty-four consecutive AHSCT recipients (17 female, 37
male) with a median age of 25 years (range, 16 to 53) who
lived at least 1 year after HSCT were included in the study.
Conditioning regimens were myeloablative in 35 patients
(64.8%) and nonmyeloablative in 19 patients (35.2%). De-
mographic, clinical, and transplantation-related character-
istics of patients are summarized in Table 1.
Eight patients (14.8%) had a history of sinusoidal
obstruction syndrome early after transplantation. Thirteen
patients (24.1%) were still on immunosuppressive treatment
during analysis.
European Group for Blood and Marrow Transplantation
risk score was <3 in 35 of 54 patients (64.8%) and3 in 19 of
54 patients (35.2%). Forty-four patients (81.5%) were in
complete remission at the time of analysis. All patients were
transfusion independent, except 4 patients with relapsed
disease. The incidence of acute GVHD, including both classic
acute and late-onset acute, was 27.8% and chronic GVHD,
including both classic and overlap syndrome, was 22.2%.
S¸.Z. Akı et al. / Biol Blood Marrow Transplant 21 (2015) 934e953950Thirteen of 54 patients (24.1%) had persistent GVHD at the
time of analysis. Liver involvement as a part of acute and
chronic GVHD was detected in 21 of 54 patients (38.9%).
Severity of chronic GVHD in 12 patients was mild in 1 (9.0%),
moderate in 6 (50.0%), and severe in 5 patients (41%). Thir-
teen of 54 patients (24.1%) were on immunosuppressive
treatment with cyclosporine A at the time of analysis. After a
median follow-up of 73 months (range, 13 to 109), 39 of 54
patients (72.2%) were alive. The cause of death was primary
disease in 12 of 54 patients (22.2%) and transplant-related
mortality in 3 of 54 patients (5.6%).
Mean serum ferritin, NTBI levels, and TS in all patients
were 1036.211572.12 ng/mL, 6.37 5.71 mg/dL, and 41.77%
 24.04%, respectively. Mean serum levels of ET-1, NO, TGF-b,
and FGF were 81.54  21.62 mmol/mL, 31.82  26.42 mmol/
mL, 2.56  .77 ng/mL, and 50.31  32.69 pg/mL, respectively.
In 19 of 54 patients (35.2%), which constitutes the high
ferritin group, serum ferritin levels were1000 ng/mL 1 year
after HSCT.
Correlation Analysis of Serum Iron Parameters and ET-1,
NO, TGF-b, and FGF Levels
Serum ferritin levels showed signiﬁcant positive correla-
tion with serum NTBI levels (r ¼ .485, P < .001) and TS (r ¼
.597, P < .001). There was a signiﬁcant negative correlation
between serum ferritin and ET-1 levels (r ¼ .271, P ¼ .05).
Serum iron parameters, including ferritin, TS, and NTBI, did
not show a correlation with serum NO (r ¼ .197, P ¼ .161; r ¼
.174, P ¼ .213; and r ¼ .032, P ¼ .819, respectively), TGF-b (r ¼
.050, P ¼ .724; r ¼ .053, P ¼ .709; and r ¼ .082, P ¼ .556,
respectively), and FGF (r ¼ .110, P ¼ .436; r ¼ .047, P ¼ .739;
and r ¼ .045, P ¼ .744, respectively). There was a signiﬁcant
negative correlation between serum ET-1 and NO levels
(r ¼ .366, P ¼ .006).
Correlation Analysis with Liver Function Test
Serum ferritin levels were positively correlated with
serum alanine aminotransferase (r ¼ .284, P ¼ .04) and g-
glutamyl transferase (r ¼ .271, P ¼ .05) levels and were nega-
tively correlatedwith serum albumin levels (r¼ .295, P¼ .03).
Serum ferritin andNTBI levelswere positively correlatedwith
prothrombin time (r ¼ .662, P ¼ .003 and r ¼ .567, P ¼ .01,
respectively). There was a signiﬁcant positive correlation
between serum TS and alanine aminotransferase levels (r ¼
.305, P¼ .03). Serum ET-1 level was positively correlatedwith
alkaline phosphatase levels (r ¼ .304, P ¼ .03).
Comparison of ET-1, NO, TGF-b, and FGF Levels between
High and Low Ferritin and TS Groups
Mean serum levels of ET-1, NO, TGF-b, and FGF were
similar in the high and low ferritin groups (P > .05). Mean
levels of TS and NTBI were signiﬁcantly higher in the high
ferritin group (57.93  25.07 versus 32.71  18.30 [P < .001]
and 10  7.61 versus 4.17  2.70 [P ¼ .004], respectively).
Serum levels of NTBI, ET-1, NO, TGF-b, and FGF were similar
in patients with TS 70% versus <70% (P > .05). Comparison
of serum levels of ﬁbrogenic mediators and iron parameters
between the 2 groups are shown in Table 2.
Comparison of Serum Iron Parameters, ET-1, NO, TGF-b,
and FGF Levels between Patients with and without
Chronic GVHD
There was a near signiﬁcant increased incidence of
chronic GVHD in the high ferritin group (P ¼ .057). However,
the incidence of chronic liver GVHD was similar between thehigh and low ferritin groups (P ¼ .721). Serum values of
ferritin, TS, NTBI, ET-1, NO, TGF-b, and FGF as continuous
variables were similar in patients with and without chronic
GVHD (P > .05). Serum albumin levels were signiﬁcantly
lower in patients with chronic GVHD (4.37  .38 versus 4.84
 .36, P¼ .001). Serum ET-1 and NO levels were similar in the
subgroup analysis of patients on and off immunosuppressive
treatment with calcineurin inhibitors (P > .05).
Survival
In univariate cox regression analysis, serum levels of iron
parameters, ET-1, NO, TGF-b, and FGF did not have an impact
on overall survival (OS) (P > .05). Serum ET-1 levels were
signiﬁcantly higher in patients with progressive disease
(76.72  10.53 mmol/mL versus 91.18  32.90 mmol/mL; 95%
conﬁdence interval [CI], .998 to 1000; P ¼ .035). Serum levels
of NO, TGF-b, and FGF did not have an impact on probability
of progression-free survival (PFS) (P > .05).
A multivariate analysis for OS was not performed because
none of the parameters showed signiﬁcant impact in uni-
variate cox regression analysis. Serum ferritin and ET-1 level
were included in multivariate Cox regression analysis and
showed that serum ET-1 was not an independent adverse
prognostic factor for the probability of PFS (P > .05). The
probability of OS was 74.3% (95% CI, 76.17 to 100.11) and
68.4% (95% CI, 57.36 to 94.53) in low and high ferritin groups,
respectively (P¼ .511) (Figure 1A). The probability of PFS was
also similar in low and high ferritin groups (56.5% [95% CI,
58.66% to 88.42%] versus 78.9% [95% CI, 64.90% to 101.30%],
respectively; P¼ .275) (Figure 1B). The probability of survival
was similar in patients with TS 70% and <70% (66.7% [95%
CI, 47.95% to 101.83%] versus 73.3% [95% CI, 75.29% to 97.54%],
respectively; P ¼ .616). The probability of OS was also similar
in patients with and without chronic GVHD (P ¼ .413).
DISCUSSION
IO and ensuing free radical production through the Fen-
ton reaction causes tissue injury in several disease and
conditions, including HSCT [19]. Several previous reports
showed IO before HSCT has an adverse impact on transplant
outcome [11,20-22]. Serum ferritin level is considered as the
surrogate marker for IO, and levels 1000 ng/mL are
accepted as high, although lower serum ferritin thresholds
are also available [13,23-25]. However, the signiﬁcance of
persistent IO after transplantation remains to be clariﬁed. A
retrospective series of 290 AHSCT recipients among whom
51% had ferritin levels above 1000 ng/mL, high ferritin levels
showed a sustained decline, reaching normal values within 5
years. Ferritin levels at different time points (namely, 0 to 6
months, 6 to 12 months, 1 to 2 years, and 2 to 5 years) were
found to be predictors of increased mortality. The adverse
impact of high levels at later time points was more promi-
nent [13]. In the current study 35.2% of recipients had serum
ferritin levels 1000 ng/mL a year after transplantation, a
frequency far less than the above-mentioned report [13].
Majhail et al. [26] reported similar results with 56 AHSCT
recipients who survived 1 year after transplantation. The
relatively small sample size and the relatively low frequency
of post-transplant IO in the present cohort might explain the
lack of an impact on survival. Increased serum ferritin levels
showed positive correlation both with TS and NTBI as ex-
pected and supporting the role of ferritin as a marker of IO.
Ferritin and TS showed a positive correlation with the
impaired liver function tests at the ﬁrst year after trans-
plantation. A negative correlation between serum ferritin
Table 1
Demographic, Clinical, and Transplantation-Related Characteristics of
Patients
Parameters Value
Male/female 37/17
Age, yr (range) 25 (16-53)
Diagnosis
Acute myeloid leukemia 21 (38.9%)
Acute lymphoblastic leukemia 5 (9.3%)
Severe aplastic anemia 13 (24.1%)
Multiple myeloma 3 (5.6%)
Lymphoma 5 (9.3%)
Chronic myelogenous leukemia 5 (9.3%)
Myelodysplastic syndrome 2 (3.7%)
Disease stages before transplantation*
Early phase 34 (63%)
Intermediate phase 16 (29.6%)
Late phase 4 (7.4%)
Median time from diagnosis to
transplantation, days (range)
237.5 (39-3018)
Donor type
Related 53 (98.1%)
Unrelated 1 (1.8%)
CD34þ cell dose, 106/kg 4.18 (1.7-8.76)
Preparative regimen
Busulfan oral/Cy 16 (29.6%)
Busulfan i.v./Cy 13 (24.1%)
TBI/Cy 5 (9.3%)
Nonmyeloablativey 20 (37.2%)
Cy indicates cyclophosphamide; TBI, total body irradiation.
* Disease stage before transplantation was categorized according to the
European Group for Blood and Marrow Transplantation criteria [17].
y Nonmyeloablative regimens consisted of ﬂudarabine-based regimens,
Cy, and Cy/antithymocyte globulin.
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bution of inﬂammation. The incidence of chronic GVHD was
higher in the high ferritin group compared with the low
ferritin group. Thus, GVHD-induced inﬂammation might
have contributed to elevated ferritin levels.
Liver dysfunction is a common complication of HSCT. In a
retrospective analysis of 121 AHSCT recipients, 52% of pa-
tients showed evidence of liver dysfunction where IO and
GVHD were the most common culprits in the late post-
transplant period. Almost all patients who underwent liver
biopsy after day 100 showed biochemical evidence of IO and
signiﬁcant hepatic iron without evidence of ﬁbrosis or
cirrhosis [27]. In another series, hepatic IO was documented
as the most common histological diagnosis of liver with an
incidence of 75% [14]. Despite the clear association with
elevated liver enzymes and IO, the association of GVHD with
IO is rather controversial [15,28-30].
Serum ferritin acts as a surrogate marker of underlying
inﬂammation as well. Although there was no correlationTable 2
Comparison of Serum Levels of Fibrogenic Mediators and Iron Parameters
Parameters Ferritin < 1000 (n ¼ 34) Ferritin  10
ET-1, mmol/mL 84.46  26.14 75.67  7.
NO, mmol/mL 31.42  27.99 30.61  23
TGF, ng/mL 2.53  .67 2.66  .9
FGF, pg/mL 50.57  35.93 49.29  27
NTBI, mg/dL 4.17  2.70 10.00  7.
Ferritin, ng/mL 382.16  313.18 1635.35  48
TS, % 32.71  18.30 57.93  25
Serum iron, mg/dL 86.61  29.47 146.52  74between serum c-reactive protein (CRP) and ferritin levels
(r ¼ .225 and P ¼ .132), the negative correlation between the
ferritin and albumin levels suggests inﬂammation might
have contributed to elevated ferritin levels. GVHD might be
partly responsible from the inﬂammatory milieu as a nega-
tive acute phase reactant serum albumin level was signiﬁ-
cantly lower in patients with chronic GVHD. The exact
implication of high ferritin levels in the inﬂammatory milieu
of the post-transplant setting might be complex and
controversial, and more precise methods to quantify tissue
iron such as magnetic resonance imaging might be required.
Serum NTBI levels at the 1-year follow-up showed sig-
niﬁcant correlation with ferritin and TS levels but did not
have a correlation with liver enzymes. Previous studies have
demonstrated increased cellular damage due to oxidative
stress mediated by NTBI early after transplantation [31].
Serum ET-1 levels showed a negative correlation with
serum ferritin and NO levels. However, levels of ET-1, NO,
TGF-b, and FGF showed no correlation with liver function
tests, at least at this time point, which is relatively short for
hepatic ﬁbrosis to develop. In conditions of oxidative stress,
reactive oxygen species attenuate ET-1einduced NO pro-
duction, causing an outweighing vasoconstriction [32]. ET-1
is released from hepatic vascular smooth muscle cells,
mesenchymal cells, endothelial cells, and stellate cells in the
damaged liver [33]. However, our results failed to show an
association between ET-1 levels and liver enzymes, although
we do not have data regarding liver histopathology. Tomis
et al. [34] evaluated the levels of circulating plasma ET-1 and
its role in the pathogenesis of HSCT-related renal and hepatic
dysfunction in 65 HSCT recipients. Despite gradually
increasing ET-1 levels from day 7 to day þ28, there was no
association between ET-1 levels and renal or hepatic
dysfunction [34].
Despite the positive correlation between ferritin and
elevated liver enzymes and the increased incidence of
chronic GVHD in the high ferritin group, there was no asso-
ciation between iron parameters and the cytokines NO and
ET-1. These results indicate that elevated serum ferritin
levels either as a marker of inﬂammation or IO might be
associated with liver dysfunction in HSCT survivors, albeit
without a relation to ﬁbrogenic cytokines. After a median
follow-up of 73 months, we failed to demonstrate any effect
of persistent IO on OS and PFS in AHSCT survivors of 1 year or
more. This compares favorably with some previous reports
[15,35]. Although IO is a common complication of HSCT,
serum ferritin might not reliably predict tissue iron. The
limitations of our study are the relatively limited sample size
and heterogeneity of underlying disorders. IO and/or the
chronic inﬂammatory status of the transplantation with the00 (n ¼ 19) P 95% CI
Lower Upper
96 .077 .97 18.55
.30 .910 13.67 15.30
3 .590 .63 .36
.70 .886 16.57 19.13
61 .004 9.58 2.05
1.10 <.001 1505.17 1001.21
.07 <.001 38.62 11.81
.78 .003 97.08 22.73
Figure 1. Probability of OS (A) and PFS (B) of patients according to ferritin levels (<1000 ng/mL versus 1000 ng/mL).
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secrete endothelin. As the negative correlation demonstrated
between serum levels of ET-1 and NO, the normal interaction
between the 2 might be disrupted in this context.
In conclusion, serum iron parameters have been shown to
positively correlate with elevated liver enzymes in survivors
of AHSCT. However, liver dysfunction showed no correlation
with ﬁbrogenic cytokines, suggesting a mild and relatively
self-limited course of liver dysfunction with the current
levels of ferritin and a relatively short follow-up that might
be too soon for ﬁbrosis to occur. Our results, similar to some
previous reports, fail to demonstrate an impact of IO on PFS
and OS. Despite the evidence of persistently elevated ferritin
in allogeneic HSCT recipients, more evidence is required to
elucidate the exact cause of elevated ferritin and to justify
iron chelation in HSCT recipients with underlying disorders
other than thalassemia.ACKNOWLEDGMENTS
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